Compare Las Vegas Sands Corp. (LVS) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Nuwellis Inc — how do they compare? Las Vegas Sands Corp. trades at $36.42 (market cap $23.38B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Las Vegas Sands Corp. is far larger — about 10627.3× Nuwellis Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Nuwellis Inc for 26 Days on average.
| LVS | NUWE | |
|---|---|---|
Market Cap | $23.38B | $2.20M |
Volume | 6,994,661 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $146.65 |
52-Week Low | $35.81 | $0.68 |
Typical Hold Time | 72 Days | 26 Days |
Enterprise Value | $35.27B | -$1.52M |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $35.81, down 1.38% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $59.78 price target, indicating significant upside potential from current levels.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and reliance on Macao's tourism sector. Near-term performance may hinge on Q3 2026 earnings and ongoing stock repurchases, while long-term growth is supported by non-gaming expansions and community initiatives in Macao.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
